Entrada Financial Statements From 2010 to 2025
| TRDA Stock | USD 10.81 0.01 0.09% |
Check Entrada Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entrada Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Entrada financial statements analysis is a perfect complement when working with Entrada Therapeutics Valuation or Volatility modules.
Entrada |
Entrada Therapeutics Company Return On Equity Analysis
Entrada Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Entrada Therapeutics Return On Equity | 0.2 |
Most of Entrada Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entrada Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Entrada Therapeutics has a Return On Equity of 0.1956. This is 100.82% lower than that of the Biotechnology sector and 100.54% lower than that of the Health Care industry. The return on equity for all United States stocks is 163.1% lower than that of the firm.
Entrada Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Entrada Therapeutics's current stock value. Our valuation model uses many indicators to compare Entrada Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entrada Therapeutics competition to find correlations between indicators driving Entrada Therapeutics's intrinsic value. More Info.Entrada Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.30 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Entrada Therapeutics is roughly 3.32 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Entrada Therapeutics' earnings, one of the primary drivers of an investment's value.About Entrada Therapeutics Financial Statements
Entrada Therapeutics stakeholders use historical fundamental indicators, such as Entrada Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Entrada Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Entrada Therapeutics' assets and liabilities are reflected in the revenues and expenses on Entrada Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Entrada Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle therapeutics for the treatment of multiple neuromuscular diseases. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Entrada Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out the analysis of Entrada Therapeutics Correlation against competitors. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.